Belite Bio stock hits all-time high at 177.28 USD
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Belite Bio Inc ADR (BLTE)
Belite Bio Inc ADR stock price live, this page displays NASDAQ BLTE stock exchange data. View the BLTE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Belite Bio Inc ADR real time stock price chart below.
What Is the Belite Bio Inc ADR Stock Price Today?
The Belite Bio Inc ADR stock price today is 175.06.
What Is the Stock Symbol for Belite Bio Inc ADR?
The stock symbol for Belite Bio Inc ADR is "BLTE."
What Stock Exchange Does Belite Bio Inc ADR Trade On?
Belite Bio Inc ADR is listed and trades on the NASDAQ stock exchange.
Is Belite Bio Inc ADR a Good Stock to Buy?
Determining whether Belite Bio Inc ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BLTE quote. (ISIN: US07782B1044)
What Is the Belite Bio Inc ADR Stock Price Today?
The Belite Bio Inc ADR stock price today is 175.06.
What Is the Stock Symbol for Belite Bio Inc ADR?
The stock symbol for Belite Bio Inc ADR is "BLTE."
What Stock Exchange Does Belite Bio Inc ADR Trade On?
Belite Bio Inc ADR is listed and trades on the NASDAQ stock exchange.
Is Belite Bio Inc ADR a Good Stock to Buy?
Determining whether Belite Bio Inc ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BLTE quote. (ISIN: US07782B1044)
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
168.00
178.00
52 wk Range
49.00
200.00
BLTE is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
168.00178.00
52 wk Range
49.00200.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BLTE Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
192.13
Upside
+9.75%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Belite Bio stock hits all-time high at $170.35
- Investing.com
- Belite Bio stock hits all-time high at 177.28 USD
- Investing.com
- Form 6K Belite Bio Inc ADR For: 27 January
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Belite Bio Inc ADR Company Profile
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Belite Bio Inc ADR Earnings Call Summary for Q2/2025
- Belite Bio beats Q2 2025 EPS expectations (-$0.31 vs -$0.39), despite widened net loss of $16.3M due to increased R&D and G&A expenses
- Strong cash position of $149.2M, bolstered by recent $15M direct offering, providing four-year runway for operations and clinical trials
- Preparing for NDA submission in H1 2026, forecasting $40-45M cash burn over next two years for potential commercialization of retinal therapies
- Stock closed slightly lower at $69.88, trading above Fair Value with analyst price targets between $80 and $110
- Focus on lesion growth rate as primary endpoint in ongoing clinical trials, with FDA recommending 24-month study completion
Last Updated: 2025-08-11, 05:14 p/m
Read Full TranscriptCompare BLTE to Peers and Sector
Metrics to compare | BLTE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLTEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −105.3x | −2.7x | −0.5x | |
PEG Ratio | 1.44 | −0.08 | 0.00 | |
Price/Book | 24.0x | 1.6x | 2.6x | |
Price / LTM Sales | - | 1.8x | 3.3x | |
Upside (Analyst Target) | 8.8% | 228.5% | 44.3% | |
Fair Value Upside | Unlock | 15.8% | 4.9% | Unlock |
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 192.13
(+9.75% Upside)
Earnings
Latest Release
Nov 10, 2025
EPS / Forecast
-0.28 / -0.50
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Belite Bio ADR (BLTE) Stock Price Today?
The Belite Bio ADR stock price today is 175.06
What Stock Exchange Does Belite Bio ADR Trade On?
Belite Bio ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Belite Bio ADR?
The stock symbol for Belite Bio ADR is "BLTE."
What Is the Belite Bio ADR Market Cap?
As of today, Belite Bio ADR market cap is 6.64B.
What Is Belite Bio ADR's Earnings Per Share (TTM)?
The Belite Bio ADR EPS (TTM) is -1.93.
When Is the Next Belite Bio ADR Earnings Date?
Belite Bio ADR will release its next earnings report on Mar 27, 2026.
From a Technical Analysis Perspective, Is BLTE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Belite Bio ADR Stock Split?
Belite Bio ADR has split 0 times.
How Many Employees Does Belite Bio ADR Have?
Belite Bio ADR has 25 employees.
What is the current trading status of Belite Bio ADR (BLTE)?
As of Feb 12, 2026, Belite Bio ADR (BLTE) is trading at a price of 175.06, with a previous close of 176.91. The stock has fluctuated within a day range of 168.00 to 178.00, while its 52-week range spans from 49.00 to 200.00.
What Is Belite Bio ADR (BLTE) Price Target According to Analysts?
The average 12-month price target for Belite Bio ADR is USD192.13, with a high estimate of USD200 and a low estimate of USD185. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +9.75% Upside potential.
What Is the BLTE After Hours Price?
BLTE's last after hours stock price is 178.53, the stock has decreased by 3.47, or 1.98%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.